glp 1 and kidneys GLP-1 the kidney: from physiology to pharmacology and outcomes in diabetes Mechanisms of GLP-1 receptor–independent renoprotective

Lisa S

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

Worldwide, nearly 40% of adults are overweight and 13% are obese

injections: Do patches work for weight loss

cGMP-compliant, custom synthesis & bulk supply

Supports Calorie Restrictive Weight Loss* Preserve Lean Muscle Mass* Support Healthy Bone Mass* Promote Healthy Hair, Skin, and Nails* Support Healthy Cognitive Function*